Vigil Neuroscience, Inc, 100 Watertown St, Ste 7, Watertown, MA 02472, US

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.